论文部分内容阅读
[目的]探讨自体外周血CD+ 造血干细胞移植治疗多发性骨髓瘤的可行性。[方法]应用CliniMACS系统分选纯化患者外周血CD+ 造血干细胞 ,用流式细胞仪检测分选纯化结果。选马法兰200mg/m2 作为预处理方案。[结果]分选纯化结果 ,单个核细胞数为3.7136×108,活性率96.6% ,CD+ 细胞数3.68018×108,即5.52×106/kg。移植后患者骨髓像获得完全缓解。移植相关并发症少且易于控制。[结论]自体外周血CD+ 造血干细胞移植治疗多发性骨髓瘤是安全、有效、可行的。
[Objective] To investigate the feasibility of autologous peripheral blood CD + hematopoietic stem cell transplantation in the treatment of multiple myeloma. [Methods] CD+ hematopoietic stem cells from peripheral blood were sorted and purified by CliniMACS system, and the results of sorting and purification were detected by flow cytometry. Mafala 200mg/m2 was selected as the pretreatment program. [Results] The results of sorting and purification showed that the number of mononuclear cells was 3.7136×108, the activity rate was 96.6%, and the number of CD+ cells was 3.68018×108, ie 5.52×106/kg. The patient’s bone marrow image was completely relieved after transplantation. Transplant-related complications are few and easy to control. [Conclusion] Autologous peripheral blood CD+ hematopoietic stem cell transplantation is safe, effective and feasible for the treatment of multiple myeloma.